Transneural Therapeutics Unveils Promising Preclinical Results for TN-001 at ACNP 2026
Transneural Therapeutics: Groundbreaking Preclinical Data on TN-001
On January 14, 2026, Transneural Therapeutics, a pioneering company in the neuroscience field, showcased compelling preclinical data for their lead candidate TN-001 during the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Nassau, Bahamas. This innovative biotechnology firm is committed to reshaping treatments for neuropsychiatric and neurodegenerative disorders, and their research on TN-001 marks a significant step forward.
Overview of TN-001's Potential
TN-001 is under development to target major depressive disorder (MDD) and post-traumatic stress disorder (PTSD), both of which present significant unmet medical needs. As emphasized by Dr. Roger McIntyre, an esteemed researcher in neuropsychiatry,
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.